Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STERITALC vs TALC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sterile talc (STERITALC) induces pleural inflammation and fibrosis, leading to adhesion of the pleural layers. This mechanism is mediated by activation of mesothelial cells and fibroblasts, resulting in release of inflammatory cytokines and growth factors.
Talc (magnesium silicate) induces pleural fibrosis and adhesion by causing an inflammatory response and fibroblast proliferation, leading to symphysis of the pleural layers.
Pleurodesis for malignant pleural effusion,Pleurodesis for recurrent pneumothorax,Pleurodesis for chylothorax (off-label)
Pleurodesis for malignant pleural effusion,Pleurodesis for recurrent pneumothorax
Sterile talc powder for intrapleural administration: 4-8 g mixed with 50-250 m L normal saline, instilled via chest tube for pleurodesis. Single dose typically used.
Intrapleural administration: 5 g mixed with 250 m L normal saline instilled via chest tube, followed by clamping for 1 hour then drainage.
Not applicable; talc particles are not metabolized and remain in the pleural space indefinitely, with gradual clearance over months to years via macrophage uptake and lymphatic drainage.
Not applicable; talc is a non-absorbable material. No systemic half-life exists; local persistence in pleural space can be months to years.
Talc is an inert mineral; not metabolized. Systemic absorption may lead to deposition in tissues, but no specific metabolic pathway exists.
Not metabolized; inert substance. Cleared by lymphatic drainage and phagocytosis by macrophages.
Sterile talc (STERITALC) is not absorbed systemically following intrapleural administration. Excretion occurs locally via phagocytosis and clearance by pleural lymphatics; no significant renal, biliary, or fecal elimination applies.
Talc is not absorbed systemically; elimination is primarily via fecal excretion of the unabsorbed material. In cases of pleural administration, talc particles are cleared by lymphatic drainage and may be phagocytized by macrophages; no significant renal or biliary excretion occurs.
Not applicable; talc is an inorganic silicate, does not bind to plasma proteins.
Not applicable; talc does not bind to plasma proteins as it is not systemically absorbed.
Not applicable; talc remains at the site of administration (pleural space) with negligible systemic distribution.
Not applicable; talc remains at site of administration (pleural space, lungs) or in GI tract; no systemic distribution.
Not applicable; administered via intrapleural instillation and acts locally. No systemic absorption is intended or occurs.
Oral: negligible (<0.1%); inhalation: minimal systemic absorption; intrapleural: not systemically available.
No dose adjustment required for renal impairment.
No dose adjustment required; talc is not significantly renally eliminated.
No dose adjustment required for hepatic impairment.
No dose adjustment required.
Safety and efficacy not established in pediatric patients; use not recommended.
Not established; safety and efficacy in children have not been determined.
No specific dose adjustment; consider general precautions for elderly due to potential comorbidities.
No specific dose adjustment; use with caution due to potential comorbidities and reduced pulmonary reserve.
Risk of acute respiratory distress syndrome (ARDS), pneumonitis, and granulomatous inflammation secondary to talc particle absorption. Use only as a sterile, asbestos-free talc slurry or poudrage. Avoid systemic absorption.
None
Use only sterile, asbestos-free talc,Monitor for respiratory distress, pneumothorax, or re-expansion pulmonary edema,Avoid in patients with empyema or active pleural infection,Caution in patients with compromised pulmonary function,Risk of fever, chest pain, and pleural effusion recurrence
Risk of acute respiratory distress syndrome (ARDS) and pneumonitis due to systemic absorption,Hypersensitivity reactions including anaphylaxis,Fever and chest pain common post-procedure,Do not use in patients with extensive pleural fibrosis or trapped lung
Hypersensitivity to talc,Pleural infection or empyema,Severe respiratory insufficiency,Pregnancy and lactation (relative contraindication),Uncontrolled bronchopleural fistula
Hypersensitivity to talc,Uncontrolled infection at the site of administration,Bronchopleural fistula,Pregnancy (relative)
No known food interactions. Maintain normal diet unless otherwise instructed by physician.
No known food interactions with intrapleural talc administration.
Insufficient human data; animal studies not conducted. Sterile talc is not absorbed systemically when used for pleurodesis, thus minimal fetal exposure. However, talc may cause maternal inflammation and fever, which could theoretically increase risk of preterm labor or fetal distress in third trimester. Use in pregnancy only if clearly needed.
No known teratogenic risk; talc is not absorbed systemically when applied topically or used perineally. No fetal harm reported in any trimester.
No data on excretion into breast milk. Due to lack of systemic absorption after pleural administration, transfer into milk is unlikely. Caution advised; consider risk-benefit.
Talc is not absorbed systemically; topical use considered safe during breastfeeding. No M/P ratio available as systemic levels are negligible.
No dose adjustment necessary due to minimal systemic absorption. Use standard pleurodesis dose (typically 2-5 g as slurry or poudrage).
No dose adjustment required for topical or perineal use; systemic levels negligible.
STERITALC (talc) is used for pleurodesis in malignant pleural effusion or recurrent pneumothorax. Administer via chest tube as a slurry or poudrage. Monitor for chest pain, fever, and hypoxia post-instillation. Ensure lung re-expansion before use to avoid trapped lung. Do not use in patients with empyema or bronchopleural fistula.
Talc is used for pleurodesis in malignant pleural effusions. Administer as intrapleural slurry via chest tube; premedicate with lidocaine to reduce pain. Monitor for fever, chest pain, and respiratory distress. Contraindicated in patients with known talc sensitivity or active infection.
You may experience chest pain, fever, or shortness of breath after the procedure.,The medication causes the layers of your lung to stick together to prevent fluid or air buildup.,Report any severe pain, difficulty breathing, or signs of infection immediately.,Avoid strenuous activity and keep the chest tube site clean and dry.,Follow up with your doctor for imaging to confirm pleurodesis effectiveness.
Talc is used to prevent fluid buildup in the chest cavity by causing the lung to stick to the chest wall.,You may experience chest pain, fever, or shortness of breath after the procedure.,Report any worsening pain, difficulty breathing, or signs of infection such as chills or fever.,This procedure is not a cure for the underlying cancer but helps manage symptoms.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STERITALC vs TALC, answered by our medical review team.
STERITALC is a Sclerosing Agent that works by Sterile talc (STERITALC) induces pleural inflammation and fibrosis, leading to adhesion of the pleural layers. This mechanism is mediated by activation of mesothelial cells and fibroblasts, resulting in release of inflammatory cytokines and growth factors.. TALC is a Sclerosing agent that works by Talc (magnesium silicate) induces pleural fibrosis and adhesion by causing an inflammatory response and fibroblast proliferation, leading to symphysis of the pleural layers.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STERITALC and TALC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STERITALC is: Sterile talc powder for intrapleural administration: 4-8 g mixed with 50-250 m L normal saline, instilled via chest tube for pleurodesis. Single dose typically used.. The standard adult dose of TALC is: Intrapleural administration: 5 g mixed with 250 m L normal saline instilled via chest tube, followed by clamping for 1 hour then drainage.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STERITALC and TALC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STERITALC is classified as Category C. Insufficient human data; animal studies not conducted. Sterile talc is not absorbed systemically when used for pleurodesis, thus minimal fetal exposure. However, talc may cause mat. TALC is classified as Category C. No known teratogenic risk; talc is not absorbed systemically when applied topically or used perineally. No fetal harm reported in any trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.